{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:32:06Z","timestamp":1786480326301,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Treatment with semaglutide improves kidney function and pathology in the mouse nephrotoxic serum nephritis model.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Transcriptomics data demonstrated that semaglutide had anti-inflammatory and antifibrotic effects and indicated beneficial effects on renal hemodynamics.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>These beneficial effects of semaglutide occur independent of metabolic effects.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CKD is a significant public health issue, affecting approximately half a billion people globally. Key risk factors for CKD include obesity, hypertension, cardiovascular diseases, and diabetes. Glucagon-like peptide-1 receptor agonists are effective treatments for obesity and diabetes. The FLOW trial recently showed that treatment with the glucagon-like peptide-1 receptor agonists semaglutide significantly reduced the incidence of clinically important kidney outcomes in patients with type 2 diabetes and CKD, likely through beneficial effects on kidney blood flow, inflammation, and fibrosis as well as effects mediated by improvement of glycemic control. This study aimed to characterize the effects of semaglutide in the mouse nephrotoxic serum nephritis model, a nonobese and nondiabetic mouse model of CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were treated with semaglutide or the angiotensin-converting enzyme inhibitor enalapril for 14 days. Various kidney function parameters were measured, and gene expression in key kidney compartments was explored using spatial transcriptomics and single-nucleus RNA sequencing in kidney samples collected at the end of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Semaglutide treatment significantly improved kidney function parameters and changed the expression of multiple genes involved in inflammatory processes and fibrosis, such as\n                      <jats:italic toggle=\"yes\">Spp1<\/jats:italic>\n                      , and also affected gene expression in the renin-angiotensin-aldosterone system. These findings from spatial transcriptomics were validated by histology, which also revealed that semaglutide decreased mesangial expansion and had a beneficial effect on filtration slit density in the glomeruli.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that the beneficial effects of semaglutide treatment in this rodent model of CKD can occur separately from its antiobesity and antidiabetes effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000001067","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:03:08Z","timestamp":1775581388000},"page":"728-740","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6173-8879","authenticated-orcid":false,"given":"Jaime Moreno","family":"Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ougaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Grancharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regitze Dalsgaard","family":"Zdravkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Viberg","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"B\u00e9nardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7116","authenticated-orcid":false,"given":"Lotte Bjerre","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-5009","authenticated-orcid":false,"given":"Charles","family":"Pyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-992X","authenticated-orcid":false,"given":"Peter Helding","family":"Kvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-4141","authenticated-orcid":false,"given":"Henning","family":"Hvid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"10225","key":"B1-20260430","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"B2-20260430","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int."},{"issue":"94","key":"B3-20260430","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1523-1755.2005.09403.x","article-title":"The epidemiology of chronic kidney disease","volume":"67","author":"Atkins","year":"2005","journal-title":"Kidney Int."},{"issue":"3","key":"B4-20260430","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000368499","article-title":"Regional variation of chronic kidney disease in Germany: results from two population-based surveys","volume":"40","author":"Aumann","year":"2015","journal-title":"Kidney Blood Press Res."},{"issue":"4","key":"B5-20260430","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2005.06.007","article-title":"Obesity and prevalent and incident CKD: the hypertension detection and follow-up program","volume":"46","author":"Kramer","year":"2005","journal-title":"Am J Kidney Dis."},{"issue":"23","key":"B6-20260430","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"12","key":"B7-20260430","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"issue":"15","key":"B8-20260430","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"12","key":"B9-20260430","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"issue":"24","key":"B10-20260430","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"24","key":"B11-20260430","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"B12-20260430","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med."},{"issue":"10","key":"B13-20260430","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B14-20260430","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Investigators: effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"6","key":"B15-20260430","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)."},{"issue":"10","key":"B16-20260430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"2","key":"B17-20260430","doi-asserted-by":"crossref","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res Clin Pract."},{"issue":"9","key":"B18-20260430","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"B19-20260430","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"B20-20260430","doi-asserted-by":"crossref","first-page":"e0168396","DOI":"10.1371\/journal.pone.0168396","article-title":"Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr-\/- mice","volume":"11","author":"Bisgaard","year":"2016","journal-title":"PLoS One."},{"issue":"7","key":"B21-20260430","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/biomedicines10071661","article-title":"Nephroprotective effects of semaglutide as mono- and combination treatment with lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease","volume":"10","author":"Dalboge","year":"2022","journal-title":"Biomedicines."},{"issue":"11","key":"B22-20260430","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000509418","article-title":"Liraglutide improves the kidney function in a murine model of chronic kidney disease","volume":"144","author":"Ougaard","year":"2020","journal-title":"Nephron."},{"issue":"3","key":"B23-20260430","doi-asserted-by":"crossref","first-page":"e00234","DOI":"10.1002\/edm2.234","article-title":"Activation of the renal GLP-1R leads to expression of Ren1 in the renal vascular tree","volume":"4","author":"Bjornholm","year":"2021","journal-title":"Endocrinol Diabetes Metab."},{"issue":"4","key":"B24-20260430","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology."},{"issue":"8","key":"B25-20260430","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.00527.2014","article-title":"Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow","volume":"308","author":"Jensen","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"B26-20260430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int."},{"issue":"2","key":"B27-20260430","doi-asserted-by":"crossref","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"key":"B28-20260430","doi-asserted-by":"crossref","first-page":"8424502","DOI":"10.1155\/2018\/8424502","article-title":"Murine nephrotoxic nephritis as a model of chronic kidney disease","volume":"2018","author":"Ougaard","year":"2018","journal-title":"Int J Nephrol."},{"issue":"3","key":"B29-20260430","first-page":"100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)."},{"key":"B30-20260430","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fmed.2018.00292","article-title":"Comparative analysis of podocyte foot process morphology in three species by 3D super-resolution microscopy","volume":"5","author":"Artelt","year":"2018","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"B31-20260430","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1369\/0022155419849388","article-title":"Extracellular matrix in kidney fibrosis: more than just a scaffold","volume":"67","author":"B\u00fclow","year":"2019","journal-title":"J Histochem Cytochem."},{"issue":"7","key":"B32-20260430","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/cells11071166","article-title":"Alterations in protein translation and carboxylic acid catabolic processes in diabetic kidney disease","volume":"11","author":"Collins","year":"2022","journal-title":"Cells."},{"issue":"9","key":"B33-20260430","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bbadis.2014.05.031","article-title":"Energy crisis: the role of oxidative phosphorylation in acute inflammation and sepsis","volume":"1842","author":"Lee","year":"2014","journal-title":"Biochim Biophys Acta."},{"issue":"3","key":"B34-20260430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(01)01542-4","article-title":"Renal effects of glucagon-like peptide in rats","volume":"434","author":"Moreno","year":"2002","journal-title":"Eur J Pharmacol."},{"issue":"7","key":"B35-20260430","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/cells11071187","article-title":"GLP-1 mediates regulation of colonic ACE2 expression by the bile acid receptor GPBAR1 in inflammation","volume":"11","author":"Biagioli","year":"2022","journal-title":"Cells"},{"issue":"10","key":"B36-20260430","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1210\/en.2014-1685","article-title":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats","volume":"156","author":"Romani-Perez","year":"2015","journal-title":"Endocrinology."},{"key":"B37-20260430","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol."},{"issue":"3","key":"B38-20260430","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10557-015-6592-7","article-title":"Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1\/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart","volume":"29","author":"Zhang","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"issue":"7","key":"B39-20260430","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"B40-20260430","doi-asserted-by":"crossref","first-page":"E641","DOI":"10.1152\/ajpendo.00429.2014","article-title":"Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men","volume":"308","author":"Asmar","year":"2015","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"4","key":"B41-20260430","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"B42-20260430","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"B43-20260430","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia."},{"issue":"8","key":"B44-20260430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"B45-20260430","doi-asserted-by":"crossref","first-page":"E744","DOI":"10.1152\/ajpendo.00518.2015","article-title":"Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy","volume":"310","author":"Asmar","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"6","key":"B46-20260430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"12","key":"B47-20260430","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/dom.12985","article-title":"Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial","volume":"19","author":"Tonneijck","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"B48-20260430","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care."},{"issue":"5","key":"B49-20260430","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/biomedicines11051356","article-title":"Osteopontin as a biomarker in chronic kidney disease","volume":"11","author":"Sinha","year":"2023","journal-title":"Biomedicines."},{"issue":"9","key":"B50-20260430","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.34067\/KID.0007352021","article-title":"Critical role of osteopontin in maintaining urinary phosphate solubility in CKD","volume":"3","author":"Stubbs","year":"2022","journal-title":"Kidney360."},{"issue":"9","key":"B51-20260430","doi-asserted-by":"crossref","first-page":"109839","DOI":"10.1016\/j.isci.2024.109839","article-title":"Kidney fibrosis molecular mechanisms Spp1 influences fibroblast activity through transforming growth factor beta smad signaling","volume":"27","author":"Ding","year":"2024","journal-title":"iScience."},{"issue":"6","key":"B52-20260430","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(\u2212\/\u2212) and LDLr(\u2212\/\u2212) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:39Z","timestamp":1786478619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001067","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-04-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}